A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

Trial Profile

A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2013

At a glance

  • Drugs Bortezomib (Primary) ; Topotecan (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top